Similarly, in AML, whose treatment relies mostly on replicative stress induced by nucleoside analogues, HSP90 inhibition reduces Chk1 and Rad51, two HSP90 client proteins that induce cell cycle arrest and promote homologous reparation repair (HR), respectively. The gene discussed is HSP90AB1; the disease is acute myeloid leukemia.